QNCXQuince Therapeutics, Inc.同业对比
Quince Therapeutics, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QNCX本股 | $28M#8 | 0.2x#2 | — | — | — | -47.8%#11 | — | — | — | — | -91.4%#15 | — |
| TVGN | $50M#1 | — | — | — | — | -91.4%#13 | — | — | — | — | -81.8%#13 | — |
| TIL | $49M#3 | — | 0.5x#2 | — | -100.0%#7 | 3.7%#5 | — | -66.5%#3 | — | — | -68.4%#10 | — |
| BKHA | $49M#4 | — | — | — | — | -30.6%#10 | — | — | — | — | 126.3%#1 | 104.1%#1 |
| SCLX | $45M#5 | — | — | 1.5x#1 | -46.5%#5 | -413.8%#15 | -1143.7%#3 | — | — | 4#1 | -71.9%#11 | — |
| MGX | $43M#6 | — | 0.4x#1 | 1.7x#2 | -51.8%#6 | -12.6%#7 | -380.9%#2 | -78.1%#5 | — | — | -37.3%#5 | — |
| ATYR | $37M#7 | — | 0.8x#4 | 197.3x#5 | -19.1%#3 | -15.8%#8 | -40856.3%#6 | -151.9%#6 | -202.0%#2 | — | -64.3%#9 | — |
| ALGS | — | — | — | — | -39.5%#4 | 81.6%#2 | -4024.9%#4 | -75.9%#4 | — | — | -43.4%#7 | — |
| ESLA | $28M#10 | — | — | — | — | — | — | — | — | — | -41.4%#6 | — |
| CVM | $26M#11 | — | 2.4x#5 | 99.9x#4 | 65.5%#1 | 5.6%#4 | -9396.5%#5 | -231.9%#7 | — | — | -84.2%#14 | — |
| GRMLW | $28M#9 | — | 0.5x#3 | — | — | -71.6%#12 | — | -18.2%#2 | -14.6%#1 | — | -33.1%#3 | — |
| JSPR | $19M#12 | — | 13.7x#9 | — | — | 100.0%#1 | — | -0.0%#1 | — | — | -76.1%#12 | — |
| PHGE | $49M#2 | 0.1x#1 | 4.5x#7 | — | — | -104.2%#14 | — | -333.2%#9 | -377.8%#3 | — | -97.9%#16 | — |
| BCDA | $19M#13 | — | 6.9x#8 | — | -100.0%#7 | -3.5%#6 | — | -304.7%#8 | — | — | -27.9%#2 | — |
| PASG | $16M#14 | — | 3.5x#6 | — | — | 29.7%#3 | — | -1021.6%#10 | — | — | -34.2%#4 | — |
| DYAI | $15M#15 | — | — | 4.8x#3 | -11.6%#2 | -26.8%#9 | -232.8%#1 | — | — | — | -59.2%#8 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议